Lotte Biologics, Excellgene to collaborate on CDO biz
Ji-Hyun Lee
Apr 03, 2023 (Gmt+09:00)
Lotte Biologics, South Korea's biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Sunday that it has entered into a memorandum of understanding (MOU) with Swiss-based cell line development company Excellgene for collaboration on contract development organization (CDO) services.
Excellgene provides cell line development services to global pharmaceutical companies and will join forces with Lotte Biologics to offer a comprehensive range of services, from cell line development to large-scale contract manufacturing of pharmaceutical cell lines.
Under the agreement, Excellgene will be responsible for cell line and high-yield process development, while Lotte Biologics will provide cell bank services and manufacture clinical and commercial pharmaceuticals.
"Enhancing CDO capabilities requires significant time and specialized personnel, but it is crucial for us to become a global CDMO company," said Lee Dong-wook, CEO of Lotte Biologics. "Through our partnership with Excellgene, which has vast experience working with leading global firms, we aim to boost not just our CMO, but also our CDO competitiveness."